Trial Profile
Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine (Primary) ; Aluminium hydroxide
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 02 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01446926).
- 02 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01446926).
- 12 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov (NCT01764126).